Kim Seulha, Lee Seunghun S, Son Boram, Kim Jeong Ah, Hwang Nathaniel S, Park Tai Hyun
School of Chemical and Biological Engineering, Institute of Chemical Processes, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea.
Interdisciplinary Program in Bioengineering, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea.
ACS Biomater Sci Eng. 2021 Mar 8;7(3):1134-1146. doi: 10.1021/acsbiomaterials.0c01349. Epub 2021 Feb 1.
An extracellular matrix (ECM) utilized as a biomaterial can be obtained from organs of living organisms. Therefore, it has some limitations in its supply because of insufficient organs. Furthermore, therapeutic efficacy of ECMs varies depending on factors such as donor's health condition and age. For this reason, ECMs obtained from a cell line could be a good alternative because they can be produced under a controlled environment with uniform quality. Thus, the purpose of this study was to investigate the potential of the MC3T3-E1 cell line-derived ECM as bone graft. The optimized decellularization process was developed to separate the ECM from MC3T3-E1, osteoblast cell line, using Trypsin-EDTA and Triton X-100. The decellularized ECM was partially digested using pepsin. Also, human bone marrow-derived mesenchymal stem cells induced faster osteogenesis on the ECM-coated surface than on the collagen-coated surface. Partially digested ECM fragments were embedded on the polyethylene glycol scaffold without additional chemical modification or crosslinking. Micro-computed tomography and histological analysis results showed that the ECM in the scaffold promoted actual bone regeneration after in vivo implantation to a mouse calvarial defect model. This study suggests that the bone-specific ECM derived from the cell line can replace the ECM from organs for application in tissue engineering and regenerative medicine.
用作生物材料的细胞外基质(ECM)可从活生物体的器官中获取。因此,由于器官供应不足,其供应存在一些限制。此外,ECM的治疗效果因供体的健康状况和年龄等因素而异。因此,从细胞系获得的ECM可能是一个很好的替代选择,因为它们可以在质量均匀的受控环境中生产。因此,本研究的目的是研究MC3T3-E1细胞系来源的ECM作为骨移植材料的潜力。开发了优化的脱细胞过程,使用胰蛋白酶-乙二胺四乙酸(Trypsin-EDTA)和曲拉通X-100从成骨细胞系MC3T3-E1中分离出ECM。使用胃蛋白酶对脱细胞后的ECM进行部分消化。此外,人骨髓来源的间充质干细胞在ECM包被的表面上比在胶原蛋白包被的表面上诱导成骨更快。部分消化的ECM片段在没有额外化学修饰或交联的情况下嵌入聚乙二醇支架中。微计算机断层扫描和组织学分析结果表明,支架中的ECM在体内植入小鼠颅骨缺损模型后促进了实际的骨再生。本研究表明,细胞系来源的骨特异性ECM可替代器官来源的ECM用于组织工程和再生医学。